$CRSP News
Last published 2d ago
- 2d agoCRSPCRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026GlobeNewswire-Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) at Day 30 in
- 2d agoCRSPCRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026GlobeNewswire-Data presented in a late-breaking oral presentation at AHA-
- 3d agoCRSPCRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune DiseasesGlobeNewswireSystemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining
- 3d agoCRSPCRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune DiseasesGlobeNewswireSystemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical...
- 1w agoCRSPCRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and ExpositionGlobeNewswireZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase
- 1w agoCRSPCRISPR Therapeutics AG - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoCRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with
- 1w agoCRSPCRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical OfficerGlobeNewswireZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective
- 3w agoCRSPCRISPR Therapeutics Announces Chief Financial Officer TransitionGlobeNewswireZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue
- 1mo agoCRSPCRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026GlobeNewswireZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene
- 1mo agoCRSPCRISPR Tx - 1774369 - CRISPR THERAPEUTICS AGEarnings Call TranscriptsHello, everyone. I'm Max Gore, a biotech analyst with Morgan Stanley. And before we get started, for important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com forward slash
- 2mo agoCRSPCRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswireZUG, Switzerland and BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that members of its senior management team will present at the Morgan Stanley 24th Annual Global
- 2mo agoCRSPCRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026GlobeNewswire-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical data for CTX310® continued to demonstrate robust, dose-dependent reductions in circulating
- 3mo agoAGMBDNTHCRSPAgomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of DirectorsGlobeNewswireAntwerp, Belgium, August 10, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced
- 3mo agoCRSPCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial ResultsGlobeNewswireZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong
- 5mo agoCRSPCRISPR Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that members of its senior management team are scheduled to participate in the following investor
- 6mo agoCRSPCRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare ConferenceGlobeNewswireZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global
- 6mo agoCRSPCRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsGlobeNewswireZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected continued
- 7mo agoCRSPCRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireZUG, Switzerland and BOSTON, April 07, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today announced that members of its senior management team will present at the 25th Annual Needham Virtual Healthcare
- 7mo agoCRSPMETATEMLegendary Investors are Rotating Capital into AI Powered BiotechGlobeNewswireDENVER, March 30, 2026 (GLOBE NEWSWIRE) -- Cathie Wood and ARK Invest are making a decisive pivot that signals where the next phase of artificial intelligence value creation may emerge: healthcare. In a series of
- 7mo agoVRTXCRSPALTARWRAnti-Aging Protein Research Takes a Step Forward with Cell CloningPR NewswireEquity-Insider.com — A protein called α-Klotho circulating in the bloodstream protects the brain, heart, kidneys, and the immune system....
- 8mo agoCRSPCRISPR Therapeutics Announces Proposed Convertible Senior Notes OfferingGlobeNewswireZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (NASDAQ:CRSP) (the "Company") today announced its intention to offer, subject to market conditions and other factors, $350 million
- 8mo agoONCYIBRXCRSPBNTX+1Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026PR NewswireEquity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in 2025 to $170.19 billion by 2032, fueled by...
- 9mo agoCRSPCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As we close out the
- 9mo agoCRSPEDITKBLBNTLACutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and MedicineGlobeNewswireDENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic diseases,
- 10mo agoCRSPCRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 MilestonesGlobeNewswire-2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading gene-editing
- 10mo agoCRSPCRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireZUG, Switzerland and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today
- 10mo agoVRTXCRSPPRMEMDGLGene Therapy: 5 Biotech Stocks Chasing the $36B PrizePR NewswireEquity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, powered by rising demand for curative treatments...
- 10mo agoCRSPCRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic MalignanciesGlobeNewswire-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose,
- 11mo agoAVAICRSPNVOVRTXFrom Insulin Injections to Functional Cures: Regenerative Medicine Reshapes DiabetesGlobeNewswireVANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford researchers achieved complete diabetes reversal in mice using a combined blood stem cell and islet transplant
- 11mo agoBEAMCRSPRCKTSDGRBeyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat ConditionsPR NewswireEquity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA...
- 11mo agoAVAICRSPSANAThe Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease CareGlobeNewswireIssued on behalf of Avant Technologies Inc. VANCOUVER, British Columbia, Nov. 19, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – The autologous cell therapy market surpassed $10.1 billion in 2025 as
- 1y agoCRSPCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswire-Positive Phase 1 data for CTX310® presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions and simultaneously published in The New England Journal of Medicine-
- 1y agoCRSPCRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid LoweringGlobeNewswire-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in circulating
- 1y agoCRSPCRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing PlatformGlobeNewswire-Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile- -The AATD program, CTX460, is the first investigational candidate to emerge from the
- 1y agoCRSPAustralia's Largest University Establishes 'Monash Boston Hub' to Accelerate Global Biotech Partnerships and LicensingBusiness WireTop‑50 global university deepens its North America and Europe collaborations to fast‑track drug discovery and health innovation. Monash University, Australia's largest and a top‑50 global research institution, today
- 1y agoCRSPCRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual CongressGlobeNewswireZUG, Switzerland and BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today
- 1y agoCRSPCRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in EuropeGlobeNewswireZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for
- 1y agoTEMCRSPBNTXBMYGlobal Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine RisesPR NewswireCell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant ...
- 1y agoCRSPCRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025GlobeNewswireZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today
- 1y agoCRSPCRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoCRSPCRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference TranscriptEarnings Call Transcripts
- 1y agoCRSPCRISPR Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireZUG, Switzerland and BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today
- 1y agoCRSP.AD.IXICSBUXCandy giant Mars partners with biotech firm to gene-edit cocoa supplyCNBCThe goal is to create cacao plants that can better withstand disease, heat and other climate-related stresses that can put global chocolate supply at risk.
- 1y agoCRSPCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsGlobeNewswire-CASGEVY® momentum building; >75 authorized treatment centers (ATCs) activated globally, achieving the target goal and ~115 patients have had cells collected across all regions; positioning the program for strong
- 1y agoCLDIVRTXIBRXCRSP+1Breaking Through: Systemic Genetic Medicines for Hard-to-Treat CancersPR NewswireEach year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is...
- 1y agoCRSPCRISPR Therapeutics Named to TIME's Most Influential Companies List of 2025GlobeNewswireZUG, Switzerland and BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, has been named
- 1y agoCRSPCRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular PipelineGlobeNewswire-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with
- 1y agoCRSPCRISPR Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced
- 1y agoCRSPCRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA TherapiesGlobeNewswire-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small interfering RNA (siRNA) for the treatment of thromboembolic